- Home
- SWIM vs NTLA Comparison
SWIM vs NTLA Comparison
Compare SWIM & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- NTLA
- Stock Information
- Founded
- SWIM 1956
- NTLA 2014
- Country
- SWIM United States
- NTLA United States
- Employees
- SWIM N/A
- NTLA N/A
- Industry
- SWIM Plastic Products
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SWIM Industrials
- NTLA Health Care
- Exchange
- SWIM Nasdaq
- NTLA Nasdaq
- Market Cap
- SWIM 839.1M
- NTLA 931.3M
- IPO Year
- SWIM 2021
- NTLA 2016
- Fundamental
- Price
- SWIM $7.27
- NTLA $8.49
- Analyst Decision
- SWIM Hold
- NTLA Buy
- Analyst Count
- SWIM 3
- NTLA 22
- Target Price
- SWIM $7.10
- NTLA $19.83
- AVG Volume (30 Days)
- SWIM 751.3K
- NTLA 8.2M
- Earning Date
- SWIM 11-04-2025
- NTLA 11-06-2025
- Dividend Yield
- SWIM N/A
- NTLA N/A
- EPS Growth
- SWIM N/A
- NTLA N/A
- EPS
- SWIM N/A
- NTLA N/A
- Revenue
- SWIM $533,235,000.00
- NTLA $57,528,000.00
- Revenue This Year
- SWIM $9.17
- NTLA $8.51
- Revenue Next Year
- SWIM $5.38
- NTLA N/A
- P/E Ratio
- SWIM N/A
- NTLA N/A
- Revenue Growth
- SWIM 4.12
- NTLA 33.52
- 52 Week Low
- SWIM $4.56
- NTLA $5.90
- 52 Week High
- SWIM $8.46
- NTLA $28.25
- Technical
- Relative Strength Index (RSI)
- SWIM 57.40
- NTLA 31.99
- Support Level
- SWIM $6.13
- NTLA $8.96
- Resistance Level
- SWIM $6.96
- NTLA $8.88
- Average True Range (ATR)
- SWIM 0.32
- NTLA 0.68
- MACD
- SWIM 0.09
- NTLA 0.15
- Stochastic Oscillator
- SWIM 98.27
- NTLA 18.97
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.